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Abstract
A report from the Keystone Symposium on Molecular and 
Cellular Biology, ‘Deregulation of transcription in cancer: control­
ling cell fate decisions’, Killarney, Ireland, 21­26 July 2009.
This Keystone meeting focused on mechanisms of trans­
criptional regulation, the effects of transcriptional 
deregulation and the consequences on cancer, and the 
possibilities for inhibiting transcription factors as potential 
therapeutic targets. Greg Verdine (Harvard University, 
Cambridge, USA) suggested that, until now, only 20% of 
the genome was targetable with drugs (druggable). 
Transcription factors have traditionally been considered 
too difficult to target, but with increased understanding of 
transcription factor biology and technological advances, 
targeting them is becoming a realistic option.
The role of polycomb complexes in regulating trans crip­
tional activity was an important theme to the meeting. 
Kristian Helin (University of Copenhagen, Denmark) sum­
marized the role of polycomb repressor complexes 
(involving EZH2) in controlling senescence, in particular 
their role in the regulation of the p16INK4A and p14ARF 
tumor suppressor proteins. Competitive binding between 
polycomb repressor complexes and the histone demethy­
lase JMJD3 determines transcriptional activity, suggesting 
that JMJD3 can act as a tumor suppressor. Maarten Van 
Lohuizen (Netherlands Cancer Institute, Amsterdam, The 
Netherlands) presented work on BMI1, a member of the 
polycomb repressor complex PRC1, which is crucial in the 
maintenance of adult stem cells. Loss of BMI1 in mouse 
models causes a dramatic reduction in proliferation in the 
mammary gland. Levels of BMI1 and EZH2 and inter­
actions between them influence tumor progression. Qiang 
Yu (Genome Institute of Singapore, Singapore) focused on 
the possibility of targeting EZH2 in cancer. Their 
compound, 3­deazaneplanocin A (DZNep), an S­adenosyl­
homocysteine hydrolase inhibitor, depletes EZH2 in breast 
cancer cells. In colorectal cancer, DZNep reactivates the 
tumor suppressor microRNA miR449, leading to cell cycle 
arrest. He suggested that DZNep, in combination with 
5­azacytidine, may be an effective cancer treatment.
Several talks used contemporary genomics technologies to 
define transcription factor binding sites, regulatory regions 
and changes in chromatin structure, all of which can 
contribute to altered cellular growth. Manel Esteller (Catalan 
Institute of Oncology, Barcelona, Spain) has assessed 
global DNA methylation in normal and cancer cells and 
found significant changes in DNA methylation at pro­
moters. He discussed the DNA epigenome project, an 
ambitious project that will study the methylation state of 
10,000 promoters in tumors from more than 1,000 
patients. Bing Ren (University of California, San Diego, 
USA) discussed global DNA methylation and histone 
modification data generated by chromatin immuno­
precipitation microarrays (ChIP­chip) or ChIP­sequencing 
(ChIP­seq). In human embryonic stem cells that were 
induced to differentiate, he showed that 30,000 putative 
enhancers exist in pre­ and post­differentiation states, but 
only 8,000 of these were common between the two states. 
Within the regions shown to have altered chromatin 
structure following differentiation, he could show enrich­
ments of motifs for various transcription factors. Both 
positive and inverse correlations were found when the 
histone maps were combined with DNA methylation data. 
Importantly, he could show that in specific cell types, 
non­CG methylation could occur and this was usually 
depleted from promoters of actively transcribed genes.
Two talks from members of the Genome Institute of 
Singapore highlighted new data on estrogen receptor (ER) 
transcription and chromatin dynamics. Yijun Ruan 
presented data on a novel technique called ‘whole genome 
chromatin interaction analysis using paired­end ditagging’ 
(ChIA­PET), which is a global method for identifying 
chromatin loops that form during transcription. By 
applying this to estrogen­induced gene transcription in 
breast cancer cells, his group found many hundreds of 
estrogen­induced intrachromosomal chromatin loops that 
form over distances as great at 1 Mb, representing cis­
regulatory components that physically interact. As a 
follow­up to this presentation, Ed Liu presented data from 
recent genome­wide mapping of ER binding sites. He 
showed that only small subsets of predicted motifs are 
actual binding sites in vivo and that the ER binding sites 
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occur in gene­rich areas. Within the list of ER binding 
sites, the strongest (that is, those most enriched by 
ChIP­seq) were more likely to contain responsive motifs 
and to be adjacent to genes that are differentially regulated 
by estrogen. This suggests that there is a hierarchy of ER 
binding sites, in which the strongest sites are more likely to 
be functional, possibly as a result of superior ER­DNA 
interactions.
Maintaining the theme of nuclear receptor transcriptional 
activity, Ralf Kittler (University of Chicago, USA) has 
engineered bacterial artificial chromosomes of more than 
20 different nuclear receptor (NR) genes to include an 
enhanced green fluorescent protein tag, and these have 
subsequently been used for genome­wide mapping using 
ChIP­chip. By correlating the binding profiles of all NRs, 
they found profile similarities and common binding sites 
between ER and retinoic acid receptor α; they hypothesized 
that this was an antagonistic interaction.
Arul Chinnaiyan (University of Michigan, Ann Arbor, USA) 
presented data characterizing gene fusions in prostate 
cancer, including his group’s original discovery of fusions 
between the TMPRSS2 gene (which encodes a trans­
membrane serine protease) and the ERG ETS­family 
oncogene in prostate cancers. He showed the results from 
large­scale genomic screens, which have resulted in more 
than 100 validated gene fusions. Interestingly, all of the 
fusions contain an ETS factor as the transcriptionally 
active partner and the other half of the fusion is usually an 
androgen­regulated gene target. He showed that fusions of 
various kinds are found in more than half of all prostate 
cancers and that their specificity to cancer and not normal 
tissue has led to a urine­based test for detecting fusion 
genes that may function as a prognostic indicator of 
prostate cancer. One of the major issues that researchers in 
the field face is defining which fusions are driving factors 
and which ones are passenger events.
One of the key themes of the meeting was the ability to 
target transcription factors using drugs. Traditionally, 
transcription factors were generally considered too difficult 
to target, and kinase pathways or cell surface proteins have 
instead been popular therapeutic targets. However, 
transcription factors are the downstream effectors of many 
pathways and this, coupled with technological advances, 
has made them attractive and realistic drug targets. Greg 
Verdine presented data on ‘stapled peptides’. Normally, 
peptides used to block or inhibit transcription factors are 
easily degraded or have poor solubility. Verdine’s approach 
provides a stabilizing backbone (or ‘staple’) to the short 
peptides or proteins, thereby generating proteins that are 
stable and maintain correct conformation. His group has 
successfully developed stapled peptides that target Bcl­2, 
Bax and BID (proapoptotic proteins containing only the 
BH­3 motif). One of their inhibitors is about to enter 
clinical trials, and the approach provides a realistic option 
for targeting a specific transcription factor in cancer.
John Rossi (Beckman Research Institute of the City of 
Hope, Duarte, USA) discussed his group’s RNA inter­
ference method as a potential therapeutic approach. He 
suggested that the delivery of small interfering RNAs 
(siRNAs) to target cells has improved considerably, but 
one of the major problems is producing sufficient 
quantities of any specific siRNA. He also showed that they 
can generate siRNAs that target two different transcripts 
simultaneously, allowing increased effectiveness from a 
single siRNA. Lyubomir Vassilev (Roche Pharmaceuticals, 
Nutley, USA) showed data on Nutlin, an inhibitor of the 
interaction between the p53 tumor suppressor and its 
regulator Mdm2. This inhibitor binds selectively to the 
pocket of Mdm2, resulting in increased p53 levels. Nutlin 
was an effective inhibitor in cell lines and in mice with 
various types of cancer and was bioavailable when 
administered orally. These data confirm that protein­
protein interactions between transcription factors and 
regulatory proteins can be blocked successfully with 
chemical inhibitors. Sandra Dunn (University of British 
Columbia, Vancouver, Canada) provided compelling 
evidence for an important role for the transcription factor 
YB­1, which is expressed in 40% of breast cancers but not 
normal breast tissue. YB­1 was shown to correlate with 
poor prognosis in patients and in mouse models, and YB­1 
transgenic mice readily generated tumors. YB­1 activity is 
dependent on phosphorylation, and Dunn’s group has 
shown that the ribosomal S6 kinase (Rsk) complex is 
involved. They are currently testing the effectiveness of 
peptides that target YB­1.
René Bernards (Netherlands Cancer Institute) stressed the 
need to be able to stratify breast cancer patients, firstly in 
order to restrict chemotherapeutic drug administration 
only to those who will benefit from it, and secondly to allow 
informed decisions regarding the choice of drug for each 
patient. As stated by Joe Nevins (Duke University Medical 
Center, Durham, USA), by finding and focusing on the 
specific subset of patients that will probably benefit from 
an individual therapy, a potential failed drug can become a 
blockbuster drug. Nevins presented gene expression 
profiles resulting from exposure to the major cancer drugs; 
from these, his group could generate signatures that 
represent a likely response or lack of response to individual 
therapies. They could use this approach to predict patients 
who would benefit from particular drug regimes. They are 
currently using these genomic screening tools in trials. 
Similarly, Bernards discussed gene expression signatures 
that predict outcome in women with breast cancer. He also 
showed data from a 159 gene signature of activated 
phosphatidylinositol 3­kinase, which was used to predict 
outcome in colon cancers. Bernards also showed data from 
a short hairpin RNA (shRNA) library screen to find genes 
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involved in resistance to trastuzumab (known as 
Herceptin) in a BT474 breast cancer cell line model. By 
simultaneously screening 24,000 human shRNAs against 
8,000 genes, his group could identify genes required for 
trastuzumab effectiveness. They identified and validated 
the phosphatase pTEN as an essential component in the 
trastuzumab response.
Clearly, the single gene or single protein approach is 
rapidly becoming redundant. The use of screens allows 
researchers to simultaneously assess all genes, identify 
thousands of regulatory sites, test a multitude of com­
pounds and combine these different screens in multi­
factorial ways. By distilling this information we can 
progress more rapidly towards personalized treatments.
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